Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 2
1985 1
1986 1
1987 3
1988 1
1989 4
1990 2
1991 1
1992 6
1993 4
1994 16
1995 14
1996 15
1997 22
1998 22
1999 23
2000 23
2001 40
2002 39
2003 60
2004 65
2005 73
2006 67
2007 89
2008 95
2009 115
2010 114
2011 122
2012 117
2013 128
2014 105
2015 112
2016 131
2017 119
2018 129
2019 103
2020 94
2021 97
2022 91
2023 77
2024 25

Text availability

Article attribute

Article type

Publication date

Search Results

2,044 results

Results by year

Filters applied: . Clear all
Page 1
Longitudinal invariance of the positive and negative syndrome scale negative dimension in antipsychotic naive first-episode schizophrenia.
Kagan S, Cogo-Moreira H, Barbosa MG, Cavalcante D, Shinji A, Noto M, Haguiara B, Cordeiro Q, Belangeiro S, Bressan RA, Noto C, Gadelha A. Kagan S, et al. Early Interv Psychiatry. 2022 May;16(5):581-586. doi: 10.1111/eip.13200. Epub 2021 Jul 15. Early Interv Psychiatry. 2022. PMID: 34265870
AIM: Construct stability over time is required for reliable inference, but evidence regarding the longitudinal invariance of negative symptoms is still limited. Thus, we examined the longitudinal invariance of the negative dimension using the positive and …
AIM: Construct stability over time is required for reliable inference, but evidence regarding the longitudinal invariance of negative …
Insight and medication adherence in schizophrenia: An analysis of the CATIE trial.
Kim J, Ozzoude M, Nakajima S, Shah P, Caravaggio F, Iwata Y, De Luca V, Graff-Guerrero A, Gerretsen P. Kim J, et al. Neuropharmacology. 2020 May 15;168:107634. doi: 10.1016/j.neuropharm.2019.05.011. Epub 2019 May 9. Neuropharmacology. 2020. PMID: 31077729 Clinical Trial.
Adherence to antipsychotic medication is critical for the treatment of patients with schizophrenia. ...Insight was assessed using the Positive and Negative Syndrome Scale (PANSS) item G12 (lack of judgment and insight). ...
Adherence to antipsychotic medication is critical for the treatment of patients with schizophrenia. ...Insight was assessed us …
What does the PANSS mean?
Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. Leucht S, et al. Schizophr Res. 2005 Nov 15;79(2-3):231-8. doi: 10.1016/j.schres.2005.04.008. Epub 2005 Jun 27. Schizophr Res. 2005. PMID: 15982856 Clinical Trial.
OBJECTIVE: Despite the frequent use of the Positive and Negative Syndrome Scale (PANSS) for rating the symptoms of schizophrenia, the clinical meaning of its total score and of the cut-offs that are used to define treatment response (e.g. at lea …
OBJECTIVE: Despite the frequent use of the Positive and Negative Syndrome Scale (PANSS) for rating the symptoms …
Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.
McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, Taylor A, Wright S. McGuire P, et al. Am J Psychiatry. 2018 Mar 1;175(3):225-231. doi: 10.1176/appi.ajp.2017.17030325. Epub 2017 Dec 15. Am J Psychiatry. 2018. PMID: 29241357 Clinical Trial.
OBJECTIVE: Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia. ...Participants were assessed before and after treatment using the …
OBJECTIVE: Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed th …
On the use of the Positive and Negative Syndrome Scale in randomized clinical trials.
Nicotra E, Casu G, Piras S, Marchese G. Nicotra E, et al. Schizophr Res. 2015 Jul;165(2-3):181-7. doi: 10.1016/j.schres.2015.04.006. Epub 2015 May 1. Schizophr Res. 2015. PMID: 25937460 Review.
In the last 25 years, the Positive and Negative Syndrome Scale (PANSS) has been largely used to assess schizophrenia symptom intensity, but little information is available on how this scale was generally applied when evaluating the effica …
In the last 25 years, the Positive and Negative Syndrome Scale (PANSS) has been largely used to assess schizo …
An Optimized Version of the Positive and Negative Symptoms Scale (PANSS) for Pediatric Trials.
Findling RL, Youngstrom EA, McClellan JM, Frazier JA, Sikich L, Daniel DG, Busner J. Findling RL, et al. J Am Acad Child Adolesc Psychiatry. 2023 Apr;62(4):427-434. doi: 10.1016/j.jaac.2022.07.864. Epub 2022 Dec 13. J Am Acad Child Adolesc Psychiatry. 2023. PMID: 36526163 Clinical Trial.
The present study's aim is to use a pediatric sample to evaluate the psychometrics of the most used primary outcome measure in pediatric schizophrenia trials, the Positive and Negative Syndrome Scale (PANSS). METHOD: To evaluate the factor struc …
The present study's aim is to use a pediatric sample to evaluate the psychometrics of the most used primary outcome measure in pediatric …
Comparison of Acute Followed by Maintenance ECT vs Clozapine on Psychopathology and Regional Cerebral Blood Flow in Treatment-Resistant Schizophrenia: A Randomized Controlled Trial.
Mishra BR, Agrawal K, Biswas T, Mohapatra D, Nath S, Maiti R. Mishra BR, et al. Schizophr Bull. 2022 Jun 21;48(4):814-825. doi: 10.1093/schbul/sbac027. Schizophr Bull. 2022. PMID: 35556138 Free PMC article. Clinical Trial.
STUDY DESIGN: In this open-label trial, 60 TRS patients were randomized equally to M-ECT (following an acute-course) or Clozapine. Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression Schizophrenia Scale (CGI-SCH), Mon …
STUDY DESIGN: In this open-label trial, 60 TRS patients were randomized equally to M-ECT (following an acute-course) or Clozapine. Positi …
Examination of Dosing of Antipsychotic Drugs for Relapse Prevention in Patients With Stable Schizophrenia: A Meta-analysis.
Leucht S, Bauer S, Siafis S, Hamza T, Wu H, Schneider-Thoma J, Salanti G, Davis JM. Leucht S, et al. JAMA Psychiatry. 2021 Nov 1;78(11):1238-1248. doi: 10.1001/jamapsychiatry.2021.2130. JAMA Psychiatry. 2021. PMID: 34406325 Free PMC article.
IMPORTANCE: The doses of antipsychotic drugs needed for relapse prevention in schizophrenia is a debated issue. ...DATA EXTRACTION AND SYNTHESIS: Using the Preferred Reporting Items for Systematic Reviews and Meta-analyses guideline, all parameters in duplicate were …
IMPORTANCE: The doses of antipsychotic drugs needed for relapse prevention in schizophrenia is a debated issue. ...DATA EXTRAC …
Initial severity of the Positive and Negative Syndrome Scale (PANSS)-30, its main subscales plus the PANSS-6, and the relationship to subsequent improvement and trial dropout: a pooled participant-level analysis of 18 placebo-controlled risperidone and paliperidone trials.
Hieronymus F, Correll CU, Østergaard SD. Hieronymus F, et al. Transl Psychiatry. 2023 Jun 7;13(1):191. doi: 10.1038/s41398-023-02491-6. Transl Psychiatry. 2023. PMID: 37286548 Free PMC article. Clinical Trial.
Greater initial severity on the 30-item Positive and Negative Syndrome Scale (PANSS-30) correlates positively with antipsychotic-placebo separation and trial dropout, but it is unknown whether these associations are present also on PANSS- …
Greater initial severity on the 30-item Positive and Negative Syndrome Scale (PANSS-30) correlates positively …
The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis.
Emsley R, Rabinowitz J, Torreman M; RIS-INT-35 Early Psychosis Global Working Group. Emsley R, et al. Schizophr Res. 2003 May 1;61(1):47-57. doi: 10.1016/s0920-9964(02)00302-x. Schizophr Res. 2003. PMID: 12648735 Review.
The Positive and Negative Syndrome Scale (PANSS) is a widely used instrument for measuring severe psychopathology in adult patients with schizophrenia. ...The forced five-factor solution essentially corresponds to the factors most frequently des …
The Positive and Negative Syndrome Scale (PANSS) is a widely used instrument for measuring severe psychopatholog …
2,044 results